Mr. Morten Albrechtsen, M.D., BBA, is the Co-founder and serves as the Chief Executive Officer at radiotherapy specialists Nanovi. Mr. Albrechtsen Founded ENKAM Pharmaceuticals A/S in 2001 and served as its Chief Executive Officer, Managing Director and Director. He serves as part-time Chief Executive Officer at a number of pharma-related startups and executive chairman at the clinical CRO NORMA. Mr. Albrechtsen served as a Managing Director of Medicometrics ApS. He is a seasoned entrepreneur and investor with a strong medical, commercial and financial background. He has great depth within most therapeutic areas and with both drugs and devices. Mr. Albrechtsen's development expertise includes all stages pre-clinical, clinical and post-market development and most disciplines. He has international commercialization expertise and has helped with sales through partners, affiliates and direct to patients, hospitals and direct to end-users. He has extensive experience with turnarounds, spinoffs, business development, licensing and corporate deals, including M&A and financing. Mr. Albrechtsen is an experienced business leader with a strong medical, commercial and financial background. After holding executive positions at several large pharmaceutical companies, including Boehringer Ingelheim and Nycomed (later acquired by Takeda Pharmaceutical). Since then, he has divided his time between consultancy work and executive roles, primarily at companies 2-4 years prior to cash-generating transactions. He served as the Chairman of Angio and NORMA A/S. He has been a Director of Blake Insomnia Therapeutics, Inc. since June 2017. He serves as a Director of Panion Animal Health AB. He serves as a Board Member of CombiGene AB (publ).

 pharma ,biotech